Maryland Stem Cell Research Fund - Validation Program

The Maryland Stem Cell Research Fund Validation Program is a state-funded initiative designed to accelerate the commercialization of human stem cell-based technologies originating from Maryland academic institutions. Administered by the Maryland Stem Cell Research Fund, the program reflects the state’s strategic priority to advance regenerative medicine and biotechnology innovation. The program specifically supports technologies that have demonstrated proof-of-concept but require additional validation to establish commercial feasibility. By bridging the gap between academic discovery and market-ready applications, the program aims to stimulate economic growth while addressing unmet medical needs. The primary objective of the Validation Program is to transition promising stem cell-based technologies from research environments into the commercial sector. Eligible projects must involve human stem cells, derivatives such as extracellular vesicles, or enabling technologies that support stem cell research. The program emphasizes projects with strong commercialization potential, including those that can be licensed to industry partners or developed into startup ventures. In addition to supporting validation studies, the program encourages collaboration across academic institutions and between academia and private-sector entities within Maryland. Funding under this program is structured to support research projects for up to two years, with a maximum primary award of 250000 dollars. Within this budget, applicants may allocate limited funds for patent-related expenses and regulatory or commercialization support services. An additional opportunity for second-tier funding allows projects to receive up to 350000 dollars if there is a formal collaboration with a Maryland-based commercial partner. This supplemental funding is contingent upon documented agreements and must be used exclusively for research conducted within the state. Indirect costs are capped at 15 percent, and projects must adhere to strict budget and reporting requirements. Eligibility is restricted to faculty members at Maryland-based universities or research institutions, excluding federal laboratories. Applicants must demonstrate that their technology addresses an unmet medical need, has been disclosed to a Technology Transfer Office, and is supported by at least one pending or issued patent owned by a Maryland institution. The intellectual property must not already be licensed or optioned to a commercial entity, and sufficient proof-of-concept data must exist to justify further validation. While collaborations are permitted, the primary applicant must meet all eligibility criteria and serve as the sole Principal Investigator for the application. The application process requires submission through the MSCRF online portal and includes a comprehensive set of components. These include detailed descriptions of the technology, commercialization strategy, research design, milestones, budget justification, and bioethics considerations. Applicants must also complete structured web form questions addressing project scope, intellectual property status, and public health impact. Strict formatting and page limits are enforced, and noncompliant applications are rejected without review. Additional documentation such as letters of collaboration and Technology Transfer Office certification is required where applicable. Applications undergo a multi-stage review process beginning with eligibility and compliance screening, followed by scientific peer review. Projects are evaluated based on scientific merit, commercialization potential, intellectual property strength, and the feasibility of the proposed research plan. High-scoring applicants are invited to present their proposals in person to a review committee composed of external experts. Final funding decisions are made by the Maryland Stem Cell Research Commission based on reviewer scores and strategic priorities. The current funding cycle requires submission by June 23, 2026 at 5 PM Eastern Time. Peer review presentations are scheduled for the week of July 27, 2026, with funding decisions announced in September 2026. Projects must be completed within 24 months of award execution. The program operates on a recurring cycle, typically offering opportunities in mid-January and mid-July each year. Applicants are encouraged to prepare early and ensure compliance with all submission requirements to avoid disqualification.

Emphasize commercialization pathway, strong intellectual property position, measurable milestones, and clear market need; ensure strict adherence to formatting and page limits